

#24
DMT
63-0**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:
Yi Li

Docket No.: PF218US

Application No.: 09/101,518

Group Art Unit: 1646

Filed: December 21, 1998

Examiner: M. Pak

For: Human G-Protein Chemokine Receptor
HSATU68

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENTCommissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorneys and/or Agents for Applicants hereby direct the Examiner's attention to references CK-CO listed on the attached Form PTO/SB/08. A copy of each of references CK-CO is enclosed.

Applicants also enclose for the Examiner's convenience a courtesy copy of references AI, CC, and CI, all previously filed in an Information Disclosure Statement on September 27, 2001.

The listed references are presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 C.F.R. § 1.104(a) concerning the Examiner's duty to consider and use any such information. Applicants respectfully request that the Examiner make the listed references of record in the file history of the application, and consider the information contained therein during the prosecution of this application.

Identification of the listed references is not to be construed an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants

Application No.: 09/101,518

Docket No.: PF218PCT


do not waive any rights to take appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Pursuant to 37 C.F.R. § 1.97(c)(2), the Patent Office will consider this Supplemental Information Disclosure Statement if filed before the mailing date of a final Office Action under §1.113, a notice of allowance under §1.311, or an action that otherwise closes prosecution in this application and accompanied by the fee set forth in § 1.17(p). Accordingly, the required fee of \$180.00 is transmitted herewith with the concurrently filed Fee Transmittal, with the appropriate fee.

If any additional fees are deemed necessary, the Patent & Trademark Office is authorized to charge the required fee to Human Genome Sciences, Inc., deposit account no 08-3425.

Dated: May 30, 2003

Respectfully submitted,

By 
Mark J. Hyman
Registration No.: 46,789
HUMAN GENOME SCIENCES, INC.
9410 Key West Avenue
Rockville, Maryland 20850
(240) 314-1224

PTO/SB/97 (12-97)

Approved for use through 9/30/00 OMB 0651-0031

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Certificate of Transmission Under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office

on May 30, 2003
Date


Signature

Mark J. Hyman - Reg. No. 46,789
Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

Applicant Initiated Interview Request Form.
Fee Transmittal (1 page), with appropriate fee;
Supplemental Information Disclosure Statement, Form PTO/SB/08, and
copies of references CK-CO;
Courtesy copies of References AI, CC, and CI; and
Certificate of Transmission Under 1.8.